Business Wire

CA-MCAFEE

17.1.2024 06:02:32 CET | Business Wire | Press release

Share
New McAfee Global Small Business Study Reveals Concerns, Knowledge and Vulnerabilities of Small Businesses in Today’s Cyber Landscape

McAfee Corp., a global leader in online protection, today announced findings from its Global Small Business Study which surveyed the owners and IT decision makers at small businesses across six countries to discover their thoughts and behavior around cybersecurity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116065441/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Business partners working together (Photo: Business Wire)

The study, conducted in collaboration with Dell Technologies, reveals cybersecurity is one of the greatest concerns of small businesses globally, with 73% of organizations saying it is one of their biggest risks or vulnerabilities. And these fears are justified. The data shows that cyberattacks are on the rise, as 44% of small businesses have experienced a cyberattack, and 17% have experienced more than one. For 67% of the organizations that experienced a cyberattack, the incident occurred in the last two years, indicating that the threat of cybercrime has become more prevalent.

For a small business, even a single cyber incident can be devastating to the bottom line. For small business owners who experienced a cyberattack, 61% lost more than $10,000 dealing with the attack. In addition, more than half (60%) of the business owners and IT decision makers indicated that the cyberattack on their business took a physical or mental toll on them and/or their staff or colleagues. In 58% of the cases, the business lost more than a week of valuable time dealing with IT issues due to the attack.

These cyberattacks have a significant impact on the finances, customer trust, and operating efficiency of small companies, causing customer data (38%), passwords (34%) or other files (34%) to be lost. Many of these attacks (43%) were caused by someone mistakenly downloading malware by clicking on a phishing link and/or opening a malicious attachment.

Unfortunately, small business owners are at a significant disadvantage when faced with malicious messages that are increasingly realistic and frequent thanks to artificial intelligence (AI). AI is a scammer's favorite tool, helping cybercriminals increase the scale, speed and sophistication of phishing and text message scams.

To help reduce AI-related concerns and anxieties about data security, small business owners need AI to beat AI. This cutting-edge technology can work in their favor to proactively protect them in real-time before they even know they have been targeted. For example, the AI-driven technology behind McAfee’s McAfee Scam Protection, proactively blocks dangerous links that appear in text messages, social media, or web browsers and allows users to engage with text messages, read emails, and browse the web peacefully and securely.

Cybersecurity Support and Responsibilities

Many small business owners understand that cyber threats are something they need to plan for and invest in mitigating. Despite their awareness, only about half (48%) of business owners/IT decision makers were fully confident in the ability of their business to prevent cyberattacks. Most small businesses (76%) manage cybersecurity without the help of others outside their business and almost half (45%) said they focus on overall general IT issues more than 7 hours a week.

McAfee and Dell’s Global Small Business Study also found:

  • Nearly one-third (24%) of business owners worry about cyberattacks daily.
  • Less than half (46%) of the business owners or IT decision makers are confident in employees’ ability to take necessary steps to protect company devices and IP.
  • A majority (68%) of small business owners believe their cybersecurity risks are increasing.
  • One-third (30%) of the small businesses that experienced cyberattacks reported the attacks occurred due to a vulnerability in outdated or unpatched software that was breached.

Resources for Small Businesses' Digital Defense

In an increasingly complex online world, the need for resources and products to help keep small business owners and their employees informed and protected online has never been greater.

McAfee’s Business Protection is a comprehensive security solution built specifically for small business owners to ensure comprehensive protection for employees, data, devices, and online connections. Launched in collaboration with Dell Technologies last year, the software helps small business customers stay ahead of cyber threats and vulnerabilities with award-winning security, identity monitoring on the dark web, VPN, web protection for safe browsing, and more. In addition to the security features McAfee Business Protection has also been designed to be extremely intuitive and is easy to use with automated protections, timely alerts, and simple user interface.

“We understand the vulnerabilities and risks small business owners face, and we’re committed to providing them industry leading online protection solutions that let them do what they do best and let us do what we do best – protect you, your data, and your customers,” said Pedro Gutierrez, Senior Vice President of Sales for McAfee.

In addition, to help educate small business professionals about the growing cyber threat landscape, and to arm them with tips to keep their data, employees, customers and livelihoods safe, McAfee and Dell have prepared a free small business resource guide.

About McAfee and Dell’s Global Small Business Study

The survey reflects the answers of 700 Business owners and IT professionals. Respondents were either top management or IT decision makers working for an organization with less than 250 employees. Respondents came from 6 countries: US, UK, Germany, France, Japan, and Australia.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116065441/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye